Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
Two major trials show kidney-protective effects for a specific IgA nephropathy group
This scoping review synthesizes evidence on SGLT2 inhibitors in IgA nephropathy.
Two large trials found kidney-protective effects for some IgA nephropathy patients taking SGLT2 inhibitors, while real-world data showed red…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
Meta-analysis and cohort study suggest association between SGLT2 inhibitors and reduced arrhythmia recurrence
SGLT2 Inhibitors Cut AF Recurrence And Improve Heart Function After Ablation
This meta-analysis and retrospective cohort study examined the association between SGLT2 inhibitors and atrial arrhythmia recurrence after c…
New data shows SGLT2 inhibitors lower the risk of irregular heartbeats returning after surgery while strengthening heart muscle in patients …
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Meta-analysis of dapagliflozin for renal outcomes in type 2 diabetes and CKD
SGLT2 inhibitors lower kidney failure risk in type 2 diabetes patients
This systematic review and meta-analysis of 10 studies synthesized evidence on dapagliflozin for renal outcomes in patients with type 2 diab…
A review of ten studies shows these drugs reduce kidney failure risk in people with type 2 diabetes and kidney disease.
Systematic review links hypertension, diabetes, and pulmonary inflammation; SGLT2 inhibitors show potential
Why Your Blood Pressure Might Be Hurting Your Lungs
This systematic review of 48 articles explores the interplay between arterial hypertension, diabetes mellitus, and pulmonary inflammation.
High blood pressure and diabetes don't just affect your heart and sugar levels; they team up to harm your lungs.
Jordan guideline review highlights SGLT2 inhibitor access barriers for heart failure patients
Heart Failure Patients Face New Insurance Hurdle for Key Drug
This mixed-methods study and guideline analysis surveyed 312 physicians in Jordan regarding prescribing decisions and insurance authorizatio…
A new study reveals that insurance rules, not medical science, are stopping heart failure patients from getting a proven treatment.
Computational model review predicts dual optima for combination therapy in ageing
New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing.
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
Meta-analysis of adjunctive SGLT2 inhibitors in type 1 diabetes shows mixed safety and efficacy signals
No More Bone Fear With New Diabetes Drug
This meta-analysis evaluated adjunctive SGLT2 inhibitor therapy in 6,731 patients with type 1 diabetes mellitus receiving insulin-based ther…
Many people with type 1 diabetes worry about their bones.
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S.
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
Taking More Heart Pills May Actually Feel Better, Not Worse
A cross-sectional study of 78 heart failure patients in a Malaysian MTAC program found SGLT2i users had significantly lower adherence (p = 0…
Heart failure patients taking more heart medicines reported feeling better, not worse, in a new study from Malaysia.